Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.

Current treatment options in oncology - 2 Jul 2021

Uddin Rehan, Darwish Noureldian H E, Mousa Shaker A

Abstract excerpt

OPINION STATEMENT: Cytogenetics and mutation identification in acute myeloid leukemia have allowed for more targeted therapy. Many therapies have been approved by the FDA in the last 3 years including gilteritinib and azacitidine but the overall survival has remained stagnant at 25%. The inability to achieve complete remission was related to the residual leukemic stem cells (LSCs). Thus, the relationship between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Susceptibility

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Tumor Microenvironment

Source

Identifiers

PMID: 34213682
DOI: 10.1007/s11864-021-00880-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.PMID 34213682Read ↗

An Overview of Targeted Therapies in Acute Myeloid LeukemiaSemantic proximity Read ↗

[Molecular targeted therapy for acute myeloid leukemia].Semantic proximity Read ↗

The biology of chronic myeloid leukemia: an overview of the new insights and biomarkersSemantic proximity Read ↗

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Semantic proximity Read ↗

Current trends in molecular diagnostics of chronic myeloid leukemiaSemantic proximity Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

Mechanisms, treatment strategies and predictive biomarkers of drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateSemantic proximity Read ↗

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature ReviewSemantic proximity Read ↗

Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature reviewSemantic proximity Read ↗

CLL1 polymeric nanoparticles loaded with PI3K/BRD4 dual inhibitor MDP5 and azacitidine as a novel treatment for TP53 mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.